Hyperparathyroidism in Chronic Kidney Disease (CKD). Secondary hyperparathyroidism of renal origin
Conditions
Interventions
Intervention group: All patients in the study received 250 mg of magnesium oxide manufactured by Exir Afarin Aria three times per week after hemodialysis for a duration of 12 weeks.
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: At least 3 months of chronic dialysis history with a standard dialysis filter and solution Receiving a stable dose of calcium carbonate, solamer, and calcitriol within the last 4 weeks (the drugs are prescribed based on the patients' serum calcium and phosphorus levels) Serum PTH level between 400 and 800 pg/mL Signed informed consent form Serum magnesium level between 1.6 and 3 mg/dL Serum calcium level between 8.5 and 10 mg/dL
Exclusion criteria
Exclusion criteria: History of Malignancy Pregnancy Breast feeding Use of Cinacalcet
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Parathyroid hormone (PTH) level. Timepoint: Before involvement and 3 months after completion of intervention. Method of measurement: Serum parathyroid hormone (PTH) levels will be measured using an ELISA kit and reported in pg/mL. | — |
Secondary
| Measure | Time frame |
|---|---|
| Magnesium. Timepoint: Before the intervention (Baseline), and subsequently at 2, 4, 8 and 12 weeks after the intervention. Method of measurement: Colorimetric method.;Calcium. Timepoint: Before the intervention (Baseline), and subsequently at 4, 8 and 12 weeks after the intervention. Method of measurement: Colorimetric method.;Phosphor. Timepoint: Before the intervention (Baseline), and subsequently at 4, 8 and 12 weeks after the intervention. Method of measurement: Colorimetric method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarzaneh Najafi
Yazd University of Medical Sciences
Outcome results
None listed